Neuland Labs - Neuland Laboratories Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Neuland Labs - Neuland Laboratories Share Price

17,056.00-142.00 (-0.83%)

Closed
As On: 15 Jun, 2026, 03:56 PM IST
As On: 15 Jun, 2026, 03:49 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	17,450.00
High	17,572.00
Low	16,980.00
Prev Close	17,198.00
Volume	37,749
VWAP(₹)	17,093.32

Key Metrics

PE Ratio(x)	60.12
EPS - TTM(₹)	283.71
MCap(₹ Cr.)	21,882.66
MCap Rank	26
PB Ratio(x)	11.77
Div Yield(%)	0.20
Face Value(₹)	10.00
52W High(₹)	19,747.00
52W Low(₹)	11,500.00
MCap/Sales	7.66
Beta(1 Month)	0.44
BV/Share(₹)	1,461.02

Neuland Labs share price insights

Dividend Announcement
Company announced a dividend of Rs 34.0 per share on May 12, 2026 with record date of Jul 24, 2026.
Quarterly Topline Performance
Company witnessed QoQ revenue growth of 76.14%, which is highest in the last 3 years. (Source: Consolidated Financials)
Buy Signal: Green flag for Bulls
Weekly stochastic crossover appeared on week ending Jun 12, 2026. Average price gain of 14.85% within 7 weeks of this signal in last 10 years.
Stock Screener Highlights
Neuland Labs is a part of Mid-cap Growth Stocks Screener
Neuland Labs Share Price Update
Neuland Laboratories Ltd. share price moved down by -0.83% from its previous close of Rs 17,198.00. Neuland Laboratories Ltd. stock last traded price is 17,056.00
Share Price Value
Today/Current/Last 17,056.0017,015.05
Previous Day 17,198.0017,177.50

Found Insights useful?

Neuland Labs Share Price Returns

1 Day	-0.83%
1 Month	2.81%
3 Months	40.36%
1 Year	29.28%
3 Years	471.14%
5 Years	720.34%

Neuland Labs Share Recommendations

Mean recosCurrent

STRONG BUY

4 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	2	2	2	2
Buy	2	2	2	2
Hold	-	-	-	-
Sell	-	-	-	-
Strong Sell	-	-	-	-
# Analysts	4	4	4	4

Recent Recos

Target₹920
OrganizationHDFC Securities
BUY

Target₹1000
OrganizationHDFC Securities
BUY

View all Stock Recommendations

News & Analysis

View all Neuland Labs Share News & Announcements

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	788.71	447.76	516.07	300.61	335.82
Total Income Growth (%)	76.14	-13.24	71.68	-10.49	-16.45
Total Expenses	494.01	386.50	381.27	278.45	294.18
Total Expenses Growth (%)	27.82	1.37	36.92	-5.35	8.17
EBIT	294.70	61.27	134.80	22.16	41.65
EBIT Growth (%)	381.02	-54.55	508.45	-46.80	-67.96
Profit after Tax (PAT)	212.67	40.57	96.85	13.90	27.81
PAT Growth (%)	424.19	-58.11	596.79	-50.01	-72.63
EBIT Margin (%)	37.36	13.68	26.12	7.37	12.40
Net Profit Margin (%)	26.96	9.06	18.77	4.62	8.28
Basic EPS (₹)	165.76	31.62	75.49	10.83	21.67

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	788.71	447.76	516.07	300.61	335.82
Total Income Growth (%)	76.14	-13.24	71.68	-10.49	-16.45
Total Expenses	494.43	386.70	381.69	278.65	294.50
Total Expenses Growth (%)	27.86	1.31	36.98	-5.38	8.20
EBIT	294.27	61.06	134.38	21.96	41.33
EBIT Growth (%)	381.94	-54.56	511.91	-46.86	-68.15
Profit after Tax (PAT)	212.52	40.42	96.46	13.71	27.73
PAT Growth (%)	425.85	-58.10	603.69	-50.57	-72.65
EBIT Margin (%)	37.31	13.64	26.04	7.31	12.31
Net Profit Margin (%)	26.95	9.03	18.69	4.56	8.26
Basic EPS (₹)	165.65	31.50	75.18	10.68	21.62

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	2,053.15	1,497.35	1,571.12	1,200.95	953.15
Total Revenue Growth (%)	37.12	-4.70	30.82	26.00	0.02
Total Expenses	1,564.17	1,227.42	1,169.69	985.20	870.99
Total Expenses Growth (%)	27.44	4.94	18.73	13.11	2.75
Profit after Tax (PAT)	364.00	260.11	300.08	163.52	63.82
PAT Growth (%)	39.94	-13.32	83.51	156.21	-20.85
Operating Profit Margin (%)	25.35	18.83	26.65	19.20	10.05
Net Profit Margin (%)	17.99	17.61	19.25	13.72	6.71
Basic EPS (₹)	283.71	202.74	233.89	127.45	49.74

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	2,053.15	1,497.35	1,571.12	1,200.95	953.15
Total Revenue Growth (%)	37.12	-4.70	30.82	26.00	0.02
Total Expenses	1,565.42	1,228.38	1,170.36	985.73	871.41
Total Expenses Growth (%)	27.44	4.96	18.73	13.12	2.76
Profit after Tax (PAT)	363.11	259.43	299.60	163.12	63.53
PAT Growth (%)	39.97	-13.41	83.67	156.75	-20.87
Operating Profit Margin (%)	25.29	18.77	26.61	19.16	10.01
Net Profit Margin (%)	17.94	17.56	19.22	13.69	6.68
Basic EPS (₹)	283.01	202.20	233.51	127.14	49.52

All figures in Rs Cr, unless mentioned otherwise

Insights

Quarterly Topline Performance
Company witnessed QoQ revenue growth of 76.14%, which is highest in the last 3 years. (Source: Consolidated Financials)
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 37.12% outperformed its 3 year CAGR of 19.36%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	2,930.14	2,179.88	1,832.56	1,579.76	1,383.49
Total Assets Growth (%)	34.42	18.95	16.00	14.19	4.43
Total Liabilities	1,055.66	655.08	549.86	585.67	542.99
Total Liabilities Growth (%)	61.15	19.14	-6.11	7.86	0.87
Total Equity	1,874.47	1,524.81	1,282.70	994.10	840.50
Total Equity Growth (%)	22.93	18.87	29.03	18.27	6.87
Current Ratio (x)	2.09	2.45	2.15	1.73	1.60
Total Debt to Equity (x)	0.10	0.09	0.06	0.12	0.28
Contingent Liabilities	0.00	92.22	140.47	100.72	92.99

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	2,928.34	2,178.17	1,830.93	1,579.34	1,382.12
Total Assets Growth (%)	34.44	18.97	15.93	14.27	4.43
Total Liabilities	1,062.49	660.38	554.39	590.97	546.55
Total Liabilities Growth (%)	60.89	19.12	-6.19	8.13	0.91
Total Equity	1,865.85	1,517.79	1,276.54	988.36	835.57
Total Equity Growth (%)	22.93	18.90	29.16	18.29	6.87
Current Ratio (x)	2.06	2.41	2.12	1.71	1.58
Total Debt to Equity (x)	0.11	0.09	0.06	0.12	0.28
Contingent Liabilities	0.00	92.22	140.47	100.72	92.99

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	346.68	317.38	261.18	237.21	58.58
Net Cash used in Investing Activities	-423.73	-298.16	-149.69	-61.50	-93.71
Net Cash flow from Financing Activities	20.98	24.96	-69.28	-135.80	37.72
Net Cash Flow	-55.26	44.36	42.16	40.32	2.66
Closing Cash & Cash Equivalent	76.67	131.93	87.58	45.42	5.09
Closing Cash & Cash Equivalent Growth (%)	-41.89	50.65	92.83	792.01	109.04
Total Debt/ CFO (x)	0.57	0.43	0.32	0.51	3.94

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	347.58	317.49	260.06	238.53	58.60
Net Cash used in Investing Activities	-423.74	-298.14	-149.67	-61.50	-93.72
Net Cash flow from Financing Activities	20.98	24.96	-69.28	-135.80	37.72
Net Cash Flow	-55.07	44.31	41.11	41.24	2.60
Closing Cash & Cash Equivalent	75.31	130.38	86.07	44.96	3.72
Closing Cash & Cash Equivalent Growth (%)	-42.24	51.49	91.44	1,109.05	233.22
Total Debt/ CFO (x)	0.57	0.43	0.32	0.51	3.94

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 423.73 cr for investing activities which is an YoY increase of 42.12%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	19.41	17.06	23.40	16.46	7.60
Return on Capital Employed (%)	23.10	16.23	29.57	20.05	9.37
Return on Assets (%)	12.42	11.93	16.37	10.35	4.61
Interest Coverage Ratio (x)	25.25	41.43	33.94	21.55	10.72
Asset Turnover Ratio (x)	0.79	0.74	0.91	0.80	0.70
Price to Earnings (x)	42.74	60.24	27.03	14.20	20.79
Price to Book (x)	8.27	10.22	6.32	2.34	1.58
EV/EBITDA (x)	25.37	44.96	16.98	8.47	10.61
EBITDA Margin (%)	29.88	23.27	30.48	23.63	15.21

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	19.46	17.10	23.48	16.51	7.61
Return on Capital Employed (%)	23.16	16.25	29.68	20.13	9.39
Return on Assets (%)	12.39	11.91	16.36	10.32	4.59
Interest Coverage Ratio (x)	25.20	41.32	33.90	21.51	10.69
Asset Turnover Ratio (x)	0.79	0.74	0.91	0.80	0.70
Price to Earnings (x)	42.74	60.24	27.10	14.25	20.88
Price to Book (x)	8.31	10.27	6.35	2.35	1.59
EV/EBITDA (x)	25.42	45.09	17.01	8.48	10.65
EBITDA Margin (%)	29.82	23.21	30.44	23.59	15.16

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
Stochastic Crossover
Bullish signal on weekly chart
Appeared on: 12 Jun 2026
Region: Overbought (Above 80)
Last Signal 2 Apr 2026 (Gain 40.75%)
Average price gain of 14.85% within 7 weeks of Bullish signal in last 10 years
5 Day EMA Crossover
Bullish signal on daily chart
Appeared on: 12 Jun 2026
5D EMA: 17054.46
Last Signal 8 Jun 2026 (Gain 2.26%)
Average price gain of 4.79% within 7 days of Bullish signal in last 5 years
Price Analysis
44%
Positive Movement
since 1st Jan 2005
on basis
54%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 17430.67 Pivot
17205.33
S1 16838.67
R2 17797.33 S2 16613.33
R3 18389.33 S3 16021.33
Average True Range
5 Days 14 Days 28 Days
512.29 575.35 600.50

Found Technicals useful?

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Neuland Labs	60.12	11.67	19.41	23.10	12.42	19.36	25.35	17.99	283.71	2.09	0.10	0.57
Wockhardt	145.53	5.87	4.31	7.66	2.47	7.82	15.89	5.89	13.12	1.66	0.43	5.45
Sai Life Science Ltd.	73.32	10.30	14.04	18.38	9.62	21.41	23.41	15.91	16.63	1.69	0.04	0.19
Eris Lifesciences	30.96	4.92	15.87	16.04	8.41	22.50	27.10	20.68	45.33	0.74	0.59	4.29
OneSource Specialty	-252.13	3.19	-1.26	0.59	-0.89	222.32	2.82	-5.19	-6.44	0.99	0.22	149.75
Add More

Annual Ratios (%)

Choose from Peers

Aarti Inds
Caplin Point
Jubilant Life
Natco Pharma
Alembic Pharma

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 41,86,984 32.63 % 0.00
Pledge 96,000 2.29 % 2.29
FII 26,24,480 20.45 % -0.44
DII 20,31,976 15.84 % 1.12
MF 14,55,556 11.35 % 0.95
Others 39,86,449 31.08 % -0.67
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 32.63 32.63 32.64 32.68
Pledge 2.29 0.00 0.00 0.00
FII 20.45 20.90 20.59 21.68
DII 15.84 14.71 13.54 11.57
Mutual Funds 11.35 10.39 9.78 7.66
Others 31.08 31.75 33.22 34.06

Mutual Funds Ownership

MF Ownership as on 31 May 2026

ICICI Pru Flexicap Direct-G
Equity: Flexi Cap
4
- 423.90
  Amount Invested (in Cr.)
- 2.00056029%
  % of AUM
- -7.86
  % Change (MoM basis)
HSBC Small Cap Direct-G
Equity: Small Cap
3
- 276.02
  Amount Invested (in Cr.)
- 1.64%
  % of AUM
- 0.00
  % Change (MoM basis)
Mahindra Manulife Multi Cap Direct-G
Equity: Multi Cap
4
- 160.17
  Amount Invested (in Cr.)
- 2.41%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Neuland Labs Top Searches

Corporate Actions

Recent
General Meeting
-
May 12, 2026
Final
340%
May 12, 2026
Board Meeting
Audited Results & Final Dividend
Apr 20, 2026

Announced on	Meeting on
Apr 20, 2026	May 12, 2026
Audited Results & Final Dividend
Jan 21, 2026	Feb 09, 2026
Quarterly Results
Oct 24, 2025	Nov 07, 2025
Quarterly Results
Jul 14, 2025	Jul 31, 2025
Quarterly Results
Apr 24, 2025	May 15, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 12, 2026 Jul 24, 2026 340%
May 15, 2025 Jul 18, 2025 120%
May 10, 2024 Jul 12, 2024 140%
May 11, 2023 Jul 11, 2023 100%
May 10, 2022 Jul 14, 2022 50%
Bonus
No Data Available
Splits
No Data Available

Announced on	Ex-Date
Feb 05, 2014	Aug 13, 2014
Rights ratio: 4 share for every 25 held at a price of Rs 204.0
Jul 07, 2011	Mar 21, 2012
Rights ratio: 5 share for every 12 held at a price of Rs 45.0
Oct 25, 1999	-
Rights ratio: 1 share for every 2 held at a price of Rs 60.0
Jan 18, 1996	Jan 22, 1996
Rights ratio: 1 share for every 2 held at a price of Rs 60.0

AGM/EGM Meetings

Announced on	Meeting on
May 12, 2026	Aug 04, 2026
-
Aug 26, 2025	Sep 28, 2025
-
May 15, 2025	Jul 30, 2025
-
May 10, 2024	Jul 31, 2024
Book closure from Jul 13, 2024 to Jul 15, 2024
May 11, 2023	Jul 27, 2023
Book closure from Jul 12, 2023 to Jul 14, 2023

About Neuland Labs

Neuland Laboratories Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 21,882.66 Crore) operating in Pharmaceuticals sector.

Neuland Laboratories Ltd. key Products/Revenue Segments include Active Pharma Ingredients, Sale of services, Export Incentives, Scrap and Other Operating Revenue for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 788.71 Crore, up 76.14 % from last quarter Total Income of Rs 447.76 Crore and up 134.86 % from last year same quarter Total Income of Rs 335.82 Crore. Company has reported net profit after tax of Rs 212.67 Crore in latest quarter.

The company’s top management includes Dr.Davuluri Rama Mohan Rao, Mr.Davuluri Saharsh Rao, Mr.Davuluri Sucheth Rao, Dr.Christopher M Cimarusti, Mr.Homi Rustum Khusrokhan, Ms.Pallavi Joshi Bakhru, Mr.Prasad Raghava Menon, Mr.Sugata Sircar, Mr.Abhijit Majumdar, Ms.Sarada Bhamidipati. Company has MSKA & Associates as its auditors. As on 31-03-2026, the company has a total of 1.28 Crore shares outstanding.

Neuland Labs Share Price Today is Rs. 17056.00. On previous day, the Neuland Labs Share Price (NSE) closed at Rs. 16973.0, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 32.63% of the stake in Neuland Labs shares, out of which 2.29% was pledged. On the same date, foreign institutional investors' (FII) holdings of Neuland Labs stocks was 20.46% as compared to 20.9% in Dec 2025 with decrease of 0.44%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 15.84% as compared to 14.71% in Dec 2025 with increase of 1.13%. Out of the total DII holdings in Neuland Labs shares 11.35% was held by mutual funds. The rest including public held is 31.07%. Neuland Labs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Neuland Labs Dividend: Ever since 1984, Neuland Labs dividends has been paid out around 26 times. As on 15 Jun, 2026, 03:56 PM IST, The overall dividend yield for Neuland Labs stands at 0.2%. The last dividend paid was on July 24, 2026 (Rs. 34.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 283.71.

Neuland Labs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 788.71 Cr. of sales and 76.14% of quarterly net profit, there have been multiple ups and downs in the Neuland Labs stock prices in the past few weeks. For example, Neuland Labs stock price on 5th of June 2026 was around Rs. 16811.0. Neuland Labs share price now stands at an average of Rs. 17056.00. Judging by last week's performance, stock is in up trend.

Neuland Labs has a median target price of Rs. 20972.0 in 12 months by 4 analysts. They have provided a high estimate of Rs. 22913.0 and low estimate of Rs. 19550.0 for Neuland Labs share.

Historical Prices and Performance:
Neuland Labs, incorporated in 1984 is a Mid Cap company (with a market cap of Rs. 22064.84) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Neuland Labs stock was 19.41%, 17.06%, 23.4%, 16.46% and 7.6% respectively.
The Neuland Labs share gave a 3 year return of 479.65% as compared to Nifty 50 which gave a return of 26.99%.
Neuland Labs announced 340.0% final dividend on July 24, 2026.

Key Metrics:
PE Ratio of Neuland Labs is 59.82
Prices/Sales Ratio of Neuland Labs is 7.66
Price/Book Ratio of Neuland Labs is 11.62

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Neuland Labs, major competitors and peers include Wockhardt, Sai Life Science Ltd., Eris Lifesciences and OneSource Specialty. As of Dec 2025, the dividend yield of Neuland Labs stands at 0.2% while Wockhardt, Sai Life Science Ltd., Eris Lifesciences and OneSource Specialty stand at 0.0%, 0.0%, 0.51% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 59.82 and 11.62 respectively.

Leadership of Neuland Labs :
Sarada Bhamidipati is Co. Secretary & Compl. Officer
Abhijit Majumdar is Chief Financial Officer
Davuluri Rama Mohan Rao is Executive Chairman
Davuluri Sucheth Rao is Vice Chairman & CEO
Davuluri Saharsh Rao is Vice Chairman & Mng.Director
Christopher M Cimarusti is Non Executive Director
Homi Rustum Khusrokhan is Ind. Non-Executive Director
Prasad Raghava Menon is Ind. Non-Executive Director
Sugata Sircar is Ind. Non-Executive Director
Pallavi Joshi Bakhru is Ind. Non-Executive Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

Nifty Smallcap 100, Nifty 500, BSE 500, BSE SmallCap, BSE Healthcare

Address

11th Floor (5th Office Level),Phoenix IVY Building,Plot No.573A-III,Hyderabad, Telangana - 500033

Contact

ir@neulandlabs.com

http://www.neulandlabs.com

Executive Leadership

DR

Davuluri Rama Mohan Rao

Executive Chairman

DS

Davuluri Saharsh Rao

Vice Chairman & Mng.Director

DS

Davuluri Sucheth Rao

Vice Chairman & CEO

CM

Christopher M Cimarusti

Non Executive Director

Show More

Auditors

MSKA & Associates

FAQs about Neuland Labs share

1. What's the Neuland Labs share price today?
Neuland Labs share price is Rs 17,056.00 as on 15 Jun, 2026, 03:56 PM IST. Neuland Labs share price is down by 0.83% based on previous share price of Rs 16,973. Neuland Labs share price trend:
- Last 12 Months: Neuland Labs share price moved up 29.28%
- Last 3 Years: Neuland Labs Share price moved up by 471.14%
2. What are the returns for Neuland Labs share?
Return Performance of Neuland Labs Shares:
- 1 Week: Neuland Labs share price moved up by 0.54%
3. What's the market capitalization of Neuland Labs?
Neuland Labs share has a market capitalization of Rs 21,882.66 Cr. Within Pharmaceuticals sector, it's market cap rank is 26.
4. What is 52 week high/low of Neuland Labs share price?
In last 52 weeks Neuland Labs share had a high price of Rs 19,747.00 and low price of Rs 11,500.00
5. What is the PE & PB ratio of Neuland Labs?
The PE ratio of Neuland Labs stands at 60.62, while the PB ratio is 11.84.

Top Gainers

As on 03:59 PM | 15 Jun 2026

498.15

57.55 (13.07%)

Kalyan Jewellers Ind

383.00

38.25 (11.10%)

1,216.20

110.50 (10.00%)

Balkrishna Ind.

2,192.50

179.41 (8.92%)

Sundaram Finance

4,466.90

307.90 (7.41%)

Top Losers

As on 03:58 PM | 15 Jun 2026

81.55

-4.30 (-5.00%)

Aurobindo Pharma

1,408.30

-64.50 (-4.38%)

108.49

-4.11 (-3.66%)

Ola Electric Mobilit

44.12

-1.63 (-3.55%)

Aster DM Health

786.70

-28.25 (-3.47%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.